|Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis|
AJ Templeton, MG McNamara, B Šeruga, FE Vera-Badillo, P Aneja, ...
JNCI: Journal of the National Cancer Institute 106 (6), 2014
|Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer|
M Scaltriti, F Rojo, A Ocaña, J Anido, M Guzman, J Cortes, S Di Cosimo, ...
Journal of the National Cancer Institute 99 (8), 628-638, 2007
|High TGFβ-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene|
A Bruna, RS Darken, F Rojo, A Ocaña, S Peñuelas, A Arias, R Paris, ...
Cancer cell 11 (2), 147-160, 2007
|Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis|
E Amir, B Seruga, S Niraula, L Carlsson, A Ocaña
Journal of the National Cancer Institute 103 (17), 1299-1309, 2011
|Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis|
AJ Templeton, O Ace, MG McNamara, M Al-Mubarak, FE Vera-Badillo, ...
Cancer Epidemiology and Prevention Biomarkers 23 (7), 1204-1212, 2014
|Drug resistance in metastatic castration-resistant prostate cancer|
B Seruga, A Ocana, IF Tannock
Nature reviews Clinical oncology 8 (1), 12, 2011
|Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis|
FE Vera-Badillo, AJ Templeton, P de Gouveia, I Diaz-Padilla, PL Bedard, ...
Journal of the National Cancer Institute 106 (1), djt319, 2013
|Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors|
JC Montero, S Seoane, A Ocaña, A Pandiella
Clinical cancer research 17 (17), 5546-5552, 2011
|Preclinical development of molecular-targeted agents for cancer|
A Ocana, A Pandiella, LL Siu, IF Tannock
Nature reviews Clinical oncology 8 (4), 200, 2011
|The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs|
S Niraula, B Seruga, A Ocana, T Shao, R Goldstein, IF Tannock, E Amir
Journal of Clinical Oncology 30 (24), 3012-3019, 2012
|Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis|
S Niraula, A Ocana, M Ennis, PJ Goodwin
Breast cancer research and treatment 134 (2), 769-781, 2012
|HER3 overexpression and survival in solid tumors: a meta-analysis|
A Ocana, F Vera-Badillo, B Seruga, A Templeton, A Pandiella, E Amir
JNCI: Journal of the National Cancer Institute 105 (4), 266-273, 2012
|When are “positive” clinical trials in oncology truly positive?|
A Ocana, IF Tannock
Journal of the National Cancer Institute 103 (1), 16-20, 2010
|Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?|
M Yu, A Ocana, IF Tannock
Cancer and Metastasis Reviews 32 (1-2), 211-227, 2013
|Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target|
JC Montero, A Ocana, M Abad, MJ Ortiz-Ruiz, A Pandiella, ...
PloS one 4 (5), e5565, 2009
|Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis|
A Ocana, F Vera-Badillo, M Al-Mubarak, AJ Templeton, ...
PloS one 9 (4), e95219, 2014
|Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer|
FE Vera-Badillo, R Shapiro, A Ocana, E Amir, IF Tannock
Annals of oncology 24 (5), 1238-1244, 2013
|Neuregulins and cancer|
JC Montero, R Rodríguez-Barrueco, A Ocaña, E Díaz-Rodríguez, ...
Clinical cancer research 14 (11), 3237-3241, 2008
|Systemic therapy for non–clear cell renal cell carcinomas: a systematic review and meta-analysis|
FE Vera-Badillo, AJ Templeton, I Duran, A Ocana, P de Gouveia, P Aneja, ...
European urology 67 (4), 740-749, 2015
|Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy|
AM Gonzalez-Angulo, SE McGuire, TA Buchholz, SL Tucker, HM Kuerer, ...
J Clin Oncol 23 (28), 7098-7104, 2005